Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Investor Presentation (September 2025)
30 slides from Sonoma Pharmaceuticals's investor presentation, Sep 29, 2025
Slide 1: Sonoma Pharmaceuticals, Inc. Investor Presentation September 2025
Sonoma Pharmaceuticals, Inc. Investor Presentation September 2025
Slide 2: Legal Disclaimers
Legal Disclaimers or INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonablene
Slide 3: About Sonoma
About Sonoma Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non - toxic disinfectants. Sonoma’
Slide 4: Hypochlorous Acid Industry Leader
Hypochlorous Acid Industry Leader Hypochlorous Acid Industry Leader 22 U.S. FDA clearances as 510(k) medical devices, transition to MDR completed for all revenue - producing products in Europe, and extensive worldwide regulatory clearances Utilized on millions of patients worldwide without a single
Slide 5: Sonoma's Microcyn Technology: Patented, Stabilized Triple-Action Topical Technology
Sonoma’s Microcyn ® Technology Patented, Stabilized Triple - Action Topical Technology • HOCl kills microbes including bacteria, fungi and viruses while assisting healing • Relieves pain and itch • Improves wound care by cleaning and moistening the wound and peri - wound area • Safely manage skin ab
Slide 6: Sonoma's Microcyn Technology: Unparalleled Safety
Sonoma’s Microcyn ® Technology Unparalleled Safety • No drug - to - drug interaction or contraindications • Millions of patients treated worldwide without a single report of serious adverse effect • 30+ human clinical trials with over 1,500 patients • Products contain all - natural hypochlorous acid
Slide 7: Research articles and case and clinical studies
Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn ® technology • Dermodacyn® Disinfecting solution study on viability of SARS - CoV - 2, see https:// www.sciencedirect.com/science/article/pii/S019567012030339X • Endocyn® study on cellula
Slide 8: Wide Range of Applications
Wide Range of Applications Wound Care Dermatology Eye Care Animal Health Care Surface Disinfectants Podiatry 8 Senior Care
Slide 9: Our Wound Care Business is Growing in the U.S. and Internationally
Our Wound Care Business is Growing in the U.S. and Internationally • Celebrating 20 years of selling wound care • In August 2024, we added Medline Industries, LP as a U.S. distributor for our wound care products – Medline is one of the largest medical supply distributors in the United States • In Oc
Slide 10: Industry-Leading Safe and Effective Dermatology Products
Industry - Leading Safe and Effective Dermatology Products • Products to relieve symptoms of atopic dermatitis, reduce scarring, and for daily skin care • Line of office dispense products targeting growing med spa market • National Eczema Association Seal of Acceptance • National Psoriasis Foundatio
Slide 11: Expanded Eye Care Product Line
Expanded Eye Care Product Line • Sonoma has the strongest FDA indications for eye care in the HOCl industry • OTC and prescription eye care sold into multiples channels • Strong MDR - compliant CE Mark for blepharitis in the EU • Animal health eye care sold in major chains including PetSmart and Tra
Slide 12: Robust U.S. and International Distribution Network
Robust U.S. and International Distribution Network OVER 40 GLOBAL PARTNERS AND GROWING We continue to: • Expand our presence in new markets by replicating what works in existing markets • Add new distribution partners and grow existing relationships • Co - develop innovative new products with partne
Slide 13: Cutting Edge Manufacturing
• 57,153 square foot state - of - the - art facility • ISO 9001, ISO 13485 and cGMP certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals • Shipping to over 55 countries, with multiple methods for shipments • Highly trained staff of 162 employees • Add
Slide 14: Manufacturing Facility
Manufacturing Facility | aN | % R i NN ai
Slide 15: Growth Strategy
Continue to introduce new high margin products Manufacturing capabilities can support significant future growth, leading to improved margins overall • Launch new applications of Sonoma’s Microcyn® technology for consumer - focused products, including in the dermatology and aesthetic space Growth Str
Slide 16: New Market Opportunities
New Market Opportunities Sonoma is expanding its partnerships and product offerings in the eye care, all - natural skin care, medical spa and animal health care industries. • The global eye care market size was estimated at USD $70.78 billion in 2023 and is projected to grow at a compound annual gro
Slide 17: Introduction of new products using our Microcyn technology
Introduction of new products using our Microcyn ® technology • In August 2025 we announced the launch of our HOCl - based diaper rash product for infants and children into and other large retailers in the United States. • In December 2024, we announced the relaunch of our prescription eye care produ
Slide 18: Expanding commercialization opportunities by investing in R&D
Expanding commercialization opportunities by investing in R&D • We successfully transitioned all of our commercialized products in Europe, including eye care , wound care , scar gel , acne products and atopic dermatitis products to the new European Union (EU) Medical Device Regulation (MDR) . • Our
Slide 19: Continuously expanding our distributor network
Continuously expanding our distributor network 19 • In January 2025, we partnered with WellSpring Pharmaceutical Corporation for the sale of our Microcyn technology - based products to large retailers in the United States . • In March, June and July 2025, we expanded our agreement with WellSpring to
Slide 20: Key Financial Metrics
Key Financial Metrics 20 Fiscal year ended March 31, 2025 - » Revenues increased 12% compared to FY 2024 » Net loss improved 29% compared to FY 2024 » EBITDA loss improved 17% compared to FY 2024 Three months ended June 30, 2025 - » Revenues increased 18% compared to same period in FY 2024 » U.S. re
Slide 21: APPENDIX: Product Portfolio
APPENDIX: Product Portfolio
Slide 22: Diverse Product Portfolio United States
Diverse Product Portfolio United States Lumacyn Clarifying Mist Microcyn Rx Skin & Wound Care Regenacyn Scar Gel Epicyn Facial Cleanser Nanocyn Hospital Grade Disinfectant Levicyn Dermal Spray, Gel & Spray Gel Celacyn Scar Management Gel Reliefacyn Itch, Burn, Rash & Pain Care Ocucyn Eyelid & Eyelas
Slide 23: U.S. Dermatology
U.S. Dermatology • Office dispense products exclusively for skin care professionals • Generates highest margins for Sonoma • Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin 23
Slide 24: U.S. Animal Health Care
U.S. Animal Health Care MicrocynAH ® family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post - surgical sites, irritated skin and lacerations. • Sold in national pet - store retail cha
Slide 25: EU Products
Epicyn ® Dermatology Gramaderm ® Dermatology Pediacyn ® Dermatology Blepharitis treatment Ocudox ® Eye lid solution Keloid or hypertrophic scar Acne treatment Atopic Dermatitis Solutions that work naturally for everybody EU Products Microdacyn60 ® Wound Care MicrocynAH ® Animal Health Care 25
Slide 26: Direct-to-consumer products available through Shopify and Amazon
Direct - to - consumer products available through Shopify and Amazon EU U.S. Products EU Products 26
Slide 27: Middle East
Middle East Microdacyn Wound Care Gil: Wi Microsafe Disinfectant & Sanitizer Microsafe Face Cool, Anti-Microbial, Baby Cool, Foot Cool, Lady Cool
Slide 28: Asia
Singapore, Malaysia, Thailand, Indonesia Wound Care South Korea BioDerm Biodacyn60 Wound Care Hong Kong China Microcyn The Philippines Microdacyn MicrocynAH ® Asia 28
Slide 29: Latin America, Australia & New Zealand
Gramacyn Kit for Acne Skin Latin America T Epicyn reat Scars Right from the Start Australia & New Zealand 29
Slide 30: Thank You
THANK YOU Sonoma Pharmaceuticals Inc. 5445 Conestoga Court, Suite 150 Boulder, CO 80301 United States of America Phone: 1 - (800) 759.9305 Email: busdev@sonomapharma.com Website: www.sonomapharma.com NASDAQ: SNOA
Sonoma Pharmaceuticals — Investor Presentation (September 2025) on 6ix